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ABSTRACT
Purpose: The principle treatment of infectious aortic aneurysm is to remove the infected aneu-
rysm and replace it with Rifampicin-soaked prosthesis by omentopecxy.  This study aimed to 
clarify the efficacy of long-term antibiotics and subsequent thoracic endovascular aneurysm re-
pair (TEVAR) for infectious thoracic aortic aneurysm.
Methods: Between July 2011 and December 2015, 213 TEVARs were performed at Hiroshima 
University Hospital.  Six patients (2.8%) had infectious aneurysm and received long-term antibi-
otic therapy and secondary TEVAR.  Long-term antibiotic therapy and subsequent TEVAR is 
paradoxical.  This study aimed to clarify the timing of TEVAR for infectious thoracic aortic an-
eurysm.
Results: All patients presented with fever and back pain, and had positive blood cultures; five 
patients had significant co-morbidities.  Bacteraemia was caused by Methicillin Sensitive Staphylo-
coccus Aureus (MSSA) (2), Streptococcus sanguinis (1), Methicillin Resistant Staphylococcus Aureus 
(MRSA) (1), Chryseobacterium meningosepticum (1), and Enterococcus faecalis (1).  Blood examina-
tion at admission revealed a WBC count ranging from 10,470 to 16,170/μl and CRP ranging from 
7.9 to 16.4 mg/dl. Long-term antibiotic therapy was continued until WBC and CRP were within 
the normal range.  TEVAR was performed emergently in 3 cases and electively in 3 cases.  The 
time from admission to TEVAR ranged from 7 to 26 days.  One stent-graft was deployed in all 6 
cases.  All patients survived and were followed for an average of 48 months; they were free from 
re-infection.
Conclusion: Long-term antibiotics and simple TEVAR may be a feasible treatment for infec-
tious thoracic aortic aneurysms.
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In cases of infectious aneurysm, open surgery 
allows for both wide debridement of infected tissue 
and extra-anatomical bypass3,4,15).  In situ rifampin-
soaked grafts, rather than extra-anatomical bypass, 
have been shown to reduce the risk of re-infection1); 
however, high mortality remains.  Thoracic endo-
vascular aneurysm repair (TEVAR) is a minimally 
invasive therapy for thoracic aortic aneurysms. 
However, the treatment potential of TEVAR for in-
fectious thoracic aneurysm is controversial because 
of the risk of prosthesis re-infection and inability 
to remove the infected aneurysm5).  This paper de-
scribes our early experiences with long-term anti-
biotic therapy and simple TEVAR for infectious 
thoracic aortic aneurysm according to the diagno-
sis of serum C-reactive protein (CRP) and white 
blood counts (WBC) and computed tomography 
(CT) angiography.  We also discuss the feasibility 
of long-term antibiotics and simple TEVAR for in-
fectious thoracic aortic aneurysm.
MATERIALS AND METHODS
This retrospective study was approved by the 
Institutional Review Board of the Hiroshima Uni-
versity Hospital.  The study complied with the 
Declaration of Helsinki, and informed consent was 
obtained from each patient.  Between 2011 and 
2015, we performed 213 TEVARs for thoracic and 
thoracoabdominal aortic aneurysms.  Six of the 
213 cases (2.8%) involved thoracic aortic aneu-
rysms with bacteraemia, including 2 impending 
ruptured aneurysms, which showed hematoma 
around abdominal aortic aneurysm and 4 growing 
aneurysms.  No patients complained of haemoptysis 
or vomiting of blood, which excluded aorto-oesopha-
geal or aorto-bronchial fistulae by CT angiography. 
The patients included 5 men and 1 woman.  Their 
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fection control.  The therapeutic sequence involves 
continuous antibiotic therapy and then TEVAR.  If 
the aneurysm is truly infected and the diameter of 
aneurysm increases rapidly, we think the risk of 
rupture is very high and perform emergent TE-
VAR.  If bacteraemia is thought to be resolved by 
antibiotic therapy, we select the clearance of infec-
tion before deploying TEVAR and first administer 
a high dose of antibiotics, and then perform TE-
VAR.  Preoperative blood culture prior to TEVAR 
showed resolution of serum bacterium in all cases. 
Serial CT angiography every 2 days was performed 
to diagnose using the above criteria.
RESULTS
The average time between admission and TE-
VAR was 14.5 days (range, 7-26 days).  Morphologi-
cally, CT angiography revealed saccular aneurysm 
(SA) in 4 cases and penetrating ulcer (PU) in 2 
cases.  Three patients underwent early TEVAR 
and 3 patients underwent elective TEVAR.  Early 
TEVAR was performed on the 7th day after admis-
sion for a case where sealed rupture of aneurysm 
was doubted (Fig. 1a, pre-TEVAR; Fig. 1b, post-
TEVAR) and for one rapidly growing aneurysm on 
day 12 of hospitalization (Fig. 2a, pre-TEVAR; Fig. 
2b, post-TEVAR).  The patient with sealed rup-
tured aneurysm presented with back pain and 
progressive anaemia.  Preoperative blood exami-
nation showed a WBC count of 11,010/μl and CRP 
level of 7.1 mg/dl.  Blood culture was positive for 
Streptococcus bacteria.  CT angiography before TE-
VAR revealed a sealed rupture of a descending 
thoracic aortic aneurysm with hematoma sur-
rounding the penetrating ulcer (Fig. 1a).  The pa-
tient received administration of antibiotics for 7 
ages ranged from 64 to 84 years (mean, 74.0 years). 
Thoracic aortic aneurysms were located in the dis-
tal aortic arch in 3 patients and the descending tho-
racic aorta in 3 patients.  Chief complaints included 
high fever (6 patients) and back pain (3 patients). 
Preoperative blood cultures revealed bacteraemia 
in all six cases.  Bacteraemia was caused by 
MSSA (2), Streptococcus sanguinis (1), MRSA (1), 
Chryseobacterium meningosepticum (1), and Entero-
coccus faecalis (1).  Preoperative blood examination 
at admission revealed a WBC count ranging from 
10,470 to 16,170/μl (mean, 12,660/μl) and CRP 
ranging from 7.1 to 16.4 mg/dl (mean, 10.8 mg/dl). 
Comorbidities included autoimmune pancreatitis 
with steroid treatment (1), central venous port in-
fection following treatment for oesophageal cancer, 
which occurred 1 month prior to TEVAR (1), ileo-
cecal resection due to cancer, which was treated 3 
months prior to TEVAR (1), chronic dialysis (1), 
and multiple sclerosis (1) (Table 1).  The patients 
with oesophageal cancer and ileocecal cancer did 
not show infectious events before admission.  All 
patients were treated with intravenous (i.v.) antibi-
otics after admission until CRP and WBC decreased 
to the normal level, but 3 patients underwent emer-
gent TEVAR during i.v. antibiotic therapy.  Causes 
of emergent TEVAR included doubt of sealed rup-
ture of the aneurysm (1 patient), and two rapidly 
growing aneurysms (Table 1).  Indication of emer-
gent TEVAR for aneurysmal growth was defined by 
rapid growth of the maximum aneurysm diameter 
compared with that measured at admission.  Elec-
tive TEVAR was performed after administration of 
i.v.  antibiotics when CRP was confirmed to have 
decreased and WBC had normalized (3 patients). 
Time from admission to TEVAR ranged from 7 
days to 26 days (mean, 14.5 days) according to in-
Table 1   Patient characteristics between emergent and elective TEVAR groups
Emergent TEVAR group
M/F Age Site morphology Bacteria at admission WBC at admission 
→ before TEVAR
CRP at admission 
→ before TEVAR
Co-morbidity
1 M  84 distal arch sac MSSA 13720    →     8680 16.4  →  3.0 autoimmune pancreatitis
2 M  75 descending sac MRSA 16170    →    10500 10.1  →  4.7 esophageal cancer
3 M  74 descending pu Streptococcus sanguinis 11010    →     6410  7.1  →  3.8 multiple sclerosis
Mean    78 13633    →     8530 11.2  →  6.2
Elective TEVAR group
El M/F Age Site morphology Bacteria at admission
WBC at admission 
→ before TEVAR
CRP at admission 
→ before TEVAR
Co-morbidity
3 M  73 distal arch sac MSSA 12120    →    7180  7.9  →  1.6 colon cancer
4 M  64 descending pu C. meningoseptium. 10470    →    5090 14.4  →  0.9 =
6 F  79 distal arch sac Enterococcus faecalis 12460    →    5870  8.7  →  2.0 cerebral infarction
Mean    72 11683    →    6047 10.3  →  1.5
Em. Emergency cases,    El, elective cases    sac, saccular aneurysm, pu, penetrating ulcer
*MSSA, methicillin-sensitive Staphylococcus aureus;
 MRSA, methicillin-resistant Staphylococcus aureus
C. meningoseptium., Chryseobacterium meningosepticum
=,  no detection
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showed Streptococcus infection, with a WBC count 
of 11,010/μl and CRP level of 7.1 mg/dl preopera-
tively.  After 7 days of antibiotic therapy, the blood 
culture showed no Streptococcus bacteria and the 
blood examination revealed that WBC count and 
CRP level decreased to 6410/μl and 2.0 mg/dl, re-
spectively (Table 1).  Another early case showed 
MSSA infection.  The WBC count of these patients 
was 13,700/μl, which decreased to 8,686/μl post-
antimicrobial therapy (Table 2).  Because the CRP 
level decrease was significant (CRP reduced from 
16.4 mg/dl to 3.0 mg/dl), we performed early TE-
VAR to prevent aneurysm rupture.  Elective cases 
showed a significant decrease of WBC count and 
CRP level after antimicrobial therapy (mean, 
11,683 to 6,047/μl in WBC count, 10.3 to 1.6 mg/dl 
in CRP level).  After TEVAR, we continued antibi-
days until the CRP level was less than 2.0 mg/dl. 
Simple TEVAR was performed using GORE-TAG 
to cover the descending aorta.  Postoperative en-
hanced CT revealed complete coverage of the lower 
descending thoracic aorta (Fig. 1b), and the subse-
quent clinical course was uneventful.  One patient 
presented with rapidly growing aneurysms (Fig. 
2a, saccular aneurysm) and received early TEVAR 
on day 12 of hospitalization (Fig. 2b).  This patient 
showed rapid aneurysm growth of more than 3 
mm in diameter compared with CT at admission 
and CRP had decreased less than 3 mg/dl.  Serial 
enhanced CT angiography was performed every 
week in all 6 cases.
We compared bacterial species and blood exami-
nations (WBC count and CRP level) pre- and post-
operatively.  The patient with sealed rupture 
Figure 1-a. Preoperative CT of ruptured aneurysm 
of the descending aorta (Case 3)
Preoperative CT demonstrated penetration of the 
descending aortic aneurysm with sealed rupture and 
hematoma
Figure 1-b. Postoperative CT after TEVAR of the 
sealed ruptured aneurysm of the descending aorta 
(Case 3)
Postoperative CT demonstrated stent-graft seal of 
the rupture site.
Figure 2-a. Preoperative CT of the rapidly growing 
aortic aneurysm (Case 1)
Preoperative CT demonstrated a rapidly growing 
aortic aneurysm.
Figure 2-b. Postoperative CT after TEVAR of the 
rapidly growing aortic aneurysm (Case 1)
Postoperative CT demonstrated that the stent-graft 
completely covered the aneurysm.
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Blood culture and CT angiography alone cannot 
differentiate between infectious aneurysms, and 
thoracic aortic aneurysms and bacteraemia.  Al-
though PET-CT can be used to differentiate these 
entities, it is unavailable for use in Japan.  We 
have thus grouped both entities under ‘thoracic 
aneurysm with bacteraemia’.  Because operative 
intervention is associated with high rates of mor-
bidity and mortality1,2,8,10,11,14) in infected aneu-
rysms, treatment with broad spectrum antibiotics is 
an essential therapy, as well as an early interven-
tion.  TEVAR is a less invasive treatment option, 
but previous reports have shown mixed results in 
patients with infectious aneurysms7,12,17).  Early 
mortality following TEVAR and late re-infection 
have ranged from 0 to 50% and 0 to 100%, respec-
tively1,7,8,10-12,14,17).  Part of the reason for the wide 
range of results is that these studies included pa-
tients with aorto-oesophageal fistulae secondary 
to erosion of the aneurysm.  Aorto-oesophageal 
and aorto-bronchial fistulae are very difficult to 
treat by simple TEVAR and are often fatal compli-
cations of infectious aneurysms, regardless of the 
treatment technique7,12,17).  Our study did not in-
clude patients with aorto-oesophageal fistulae or 
aorto-bronchial fistulae.  That is why we observed 
100% survival and absence of re-infection.  We per-
formed 3 emergent TEVAR and 3 elective TEVAR 
procedures according to the patient’s condition.  If 
the patient showed rapid growth of the aneurysm 
as evaluated by serial CT angiography (aneurys-
mal growth >3 mm compared with the diameter 
measured at admission), we performed emergent 
TEVAR.  If the aneurysm diameter measured by 
serial CT angiography was unchanged after ad-
mission, we selected antibiotic therapy first until 
the clearance of bacteraemia was confirmed.  The 
extended duration of antibiotic therapy might also 
otic therapy; the final blood examination showed 
5,800/μl for WBC count and 0.9 mg/dl for CRP lev-
el at discharge.  The mean hospital stay was 38 
days.
Several types of stent-grafts were used in the 6 
cases: GORE-TAG (Gore corp.) in 3 cases, TX2 
(Cook corp.) in 2 cases, and C-TAG (Gore corp.) in 
1 case.  One stent-graft (length, 10 to 20 cm; di-
ameter; 28 to 36 mm) was deployed toward the an-
eurysm in all 6 cases.  The proximal landing zone 
ranged from zone 2 to Th9.  The artery of Adam-
kiewicz was identified by CT angiography preoper-
atively and covered in 3 patients, but no spinal 
cord injury was observed.  Days to TEVAR were 
12 days in the early TEVAR cases and 21 days in 
the elective TEVAR cases.  There was a significant 
difference in days to TEVAR between groups (Ta-
ble 2).  However, postoperative stay was same be-
tween groups.  All patients survived without any 
serious complications.  The median post-procedur-
al hospital stay was 22 days (range, 14-34 days).
 Intravenous antibiotic treatment was tailored 
to the causative organism in all cases, and i.v. 
treatment lasted a mean 22 days.  Cefazolin was 
used for 12 to 30 days in 4 patients.  Vancomycin 
plus carbapenem was administered for 21 days in 
a patient with MRSA infection.  Penicillin-G was 
used for 30 days in a patient with streptococcal in-
fection.  Oral antibiotics (oral penicillin or cefalo-
sporin) were administered throughout treatment. 
At a median 48 months of follow-up (range, 26-68 
months), all patients were alive with no clinical 
sign of re-infection (Table 2).
DISCUSSION
Infectious thoracic aortic aneurysm is among 
the most challenging aortic aneurysms to treat. 
Table 2  Characteristics of procedure (comparison with emergent and elective TEVAR groups)
Emergent TEVAR group
No. Em Aneurysm growth Device x number
Bacteria at 
TEVAR
Days to 
TEVAR Access Pro. landing AKA cover
Hosp. after 
TEVAR Result
1. Em 3mm at 10th day C-TAGx1 no 10 rt.FA Zone2 = 34 good
2. Em 3mm at 11th day TAG x1 no 12 rt.FA Th5 Th8 15 good
3. Em sealed rupture TAG x1 no  7 rt.FA Th9 Th12 17 good
Mean  9.7 22
Elective TEVAR group
No. El Aneurysm growth Device x number
Bacteria at 
TEVAR
Days to 
TEVAR Access Pro. landing AKA cover
Hosp. after 
TEVAR Result
4. El no growth at 14th day TX2 x1 no 18 rt.FA Zone3 = 16 good
5. El no growth at14th day TX2 x1 no 19 lt.FA Th6 Th9 31 good
3. El no growth at 21th day TAG x1 no 26 abdominal aorta Zone2 = 14 good
Mean 21 20
* Em, emergency cases; El, elective cases; days to TEVAR, days from admission to TEVAR (Thoracic endovascular aneurysm 
repair); rt.FA, right femoral artery; Pro.landing, proximal landing zone; AKA, Adamkiewicz artery; Th, thoracic vertebrae; 
EVAR, endovascular aneurysm repair
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cur during the late phase.  Once endograft infection 
occurs, the treatment should be performed with 
complete exclusion of the endograft and surgical re-
placement of the whole infected aorta6).  Long-term 
oral antibiotic therapy may reduce the likelihood 
of the emergence and spread of multidrug-resis-
tant organisms, which poses a serious threat to 
hospitalized individuals.  Restricting the use of 
one antibiotic often requires a compensatory in-
crease in the use of another antibiotic, which in 
turn selects for the emergence of different species 
of multidrug-resistant organisms; furthermore, 
the potential clinical implications of such interac-
tions remaining largely unexplored16).  However, 
endograft infection is fatal in TEVAR.  Thus, we 
continued one antibiotic for at least 6 months. 
Fortunately, TEVAR and long-term antibiotic 
therapy alone was feasible in our cases.  Although 
our experience included only 6 patients and was 
limited to aortic aneurysms without fistulae to 
visceral organs, our strategy may be effective in 
limited cases with aortic aneurysms with bacter-
aemia.  Serial CT angiography help select emer-
gent TEVAR or elective TEVAR for the treatment 
of aortic aneurysm with bacteraemia.
CONCLUSION
Simple TEVAR and long-term antibiotics effec-
tively treated patients with thoracic aortic aneu-
rysms with bacteraemia.  We observed 100% early 
and late survival and no re-infection.  It is impor-
tant to perform this strategy when indicated; the 
time of TEVAR and antibiotic administration for 
infected thoracic aortic aneurysm is also crucial. 
Further study is mandatory.
DISCLOSURE STATEMENT
All authors declare that they have no conflicts of 
interest.
(Received August 17, 2017)
(Accepted October 10, 2017)
REFERENCES
1. Blocker, D., Schmacher, H., Schwarzbach, M., 
Ockert, S., Robert, H. and Allenberg, J.R. 2004. 
Endoluminal stent-graft repair of aorto-bronchial 
fistulas: bridging or defining long-term solution?  J 
Endovasc Ther 11:41-48.
2. Gonzalez-Fajardo, J.A., Gutierrez, V., Martin- 
Pedrosa, M., Del Rio, L. Carrera, S. and Vaquero, C. 
2005. Endovascular repair in the presence of aortic 
infection. Ann Vasc Surg 19:94-98.
3. Hsu, R.B. and Lin, F.Y. 2008. Infected aneurysm of 
the thoracic aorta. J Vasc Surg 47:270-276.
4. Hsu, R.B. and Lin, F.Y. 2007. Surgery for infected 
aneurysm of the aortic arch. J Thorac Cardiovasc 
Surg 134:1157-1162.
explain the excellent outcomes we observed1,8,10,11). 
Stent-grafts are deployed and maintained in an 
infected field9), and long-term administration of 
antibiotics may decrease the risk of re-infection. 
Our experience suggests that oral antibiotic treat-
ment should last for at least 6 months to prevent 
re-infection and continue indefinitely.  We selected 
emergency TEVAR cases by establishing sealed 
rupture and rapid growth of the aneurysm (>3 
mm growth in diameter compared to the diameter 
measured in preoperative CT angiography).  We 
wondered why simple TEVAR and antibiotic thera-
py could eliminate aneurysm with bacteraemia 
without late infection.  We suppose it is because 
the porosity of the TEVAR graft is large and can 
allow permeation of antibiotics between the blood 
and infected aneurysm.  Thus, the antibiotics can 
easily diffuse through the stent-graft wall, reach 
the aneurysmal sac, and destroy the microorgan-
isms.  Long-term use of antibiotics may also control 
infection and prevent late recurrence of infection.
There are several reports of surgical interven-
tion for infectious aneurysms from Southern-east-
ern Asian countries15,17).  Some were performed by 
surgical exclusion of the aneurysm and prosthetic 
replacement with omental wrapping17).  The dis-
ease-specific mortality was very high (31.25%) in 
infected abdominal aortic aneurysms when con-
ventional surgery was performed13).  Endovascular 
repair and long-term antibiotics may be feasible for 
both infected thoracic and abdominal aortic aneu-
rysms18).  Treatment strategies for prosthesis infec-
tion has evolved recently, but complete excision of 
the infected stent-graft and surrounding tissue is 
mandatory once stent-graft infection occurs6).  Al-
though antibiotic therapy alone for infectious aneu-
rysm is dangerous due to the risk of rupture, we 
think simple TEVAR and antibiotic therapy is fea-
sible for aneurysms with bacteraemia.  The timing 
of TEVAR for infected aneurysms is controversial. 
Infection should be eliminated using antibiotics be-
fore TEVAR.  However, some patients require 
emergent TEVAR because of impending rupture. 
Serial CT angiography is useful to determine if the 
aneurysm is dangerous.  The morphology of the an-
eurysm (saccular or penetrating ulcer) and the 
growth rate of the aneurysm diameter as measured 
by CT angiography may indicate the risk of rupture 
of the aneurysm.  Although the number of our pa-
tients was very small, this study suggests a treat-
ment for thoracic aneurysm with bacteraemia using 
TEVAR and antibiotic therapy.
We used i.v. antibiotic therapy until the fever re-
solved and WBC count was normalized.  In 3 cas-
es, emergent TEVAR was performed during i.v. 
antibiotic therapy.  In the other 3 cases, elective 
TEVAR was performed after resolution of bacter-
aemia.  Bacteraemia resolved in all 6 cases and we 
observed no infection-related complications.  While 
the incidence of TEVAR infection is rare, it can oc-
108 S. Takahashi et al
pulmonary fistulas. J Vasc Surg 50:992-998.
13. Sorcline, K., Mani, K., Bjork, M., Nyman, R. and 
Wanhaninen, A. 2009. Endovascular repair of in-
fectious aortic aneurysms. J Vas Surg 50:269-274.
14. Ting, A.C., Cheng, S.W., Ho, P. and Poon, J.T. 
Cheung, G.C. 2006. Endovascular stent-graft re-
pair for infected thoracic aortic pseudoaneurysm – a 
durable option ?  J Vasc Surg 44:701-705.
15. Von Segesser, L.K., Tkebuchava, T., Niederhauser, 
U., Kunzli, A., Lachat, M., Genoni, M,, et al. 1997. 
Aortoaorto-bronchial and aortoaorto-esophageal fis-
tulae as risk factors in surgery of descending tho-
racic aortic aneurysms. Eur J Cardiothorac Surg 
12:195-201.
16. Wang, J., Foxman, B., Mody, L. and Snikin, E.S. 
2017. Network of microbial and antibiotic interac-
tions drive colonization and infection with multi-
drug-resistant organisms. Proc Natl Acad Sci USA 
DOI 10. 1073/pnas.171023114 [Epub ahead of print].
17. Wheatley, G.H, Nimesz, A., Preventza, O., Ramatah, 
V.G., Rodngez-Lopez, J.A., William, J., et al. 2007. 
Have we gone too far ? Endovascular stent-graft re-
pair of aorto-bronchial fistulae. J Thorac Cardiovasc 
Surg 133:1277-1285.
18. Yamasaki, M., Abe, K., Misumi, H., Ito, J., Nakanishi, 
Y. and Kawazoe, K. 2015. Endograft infection after 
hybrid surgery for chronic Stanford type B aortic 
dissection: endograft infection and treatment. Surg 
Today 45;1575-1578.
5. Heneghan, R.E, Singh, N. and Stames, B.W. Suc-
cessful emergent endovascular repair of a ruptured 
infectious thoracic aortic aneurysm. Ann Vas Surg 
2015;29(4):843
6. Igari, K., Kudo, T., Toyofuku, T., Jibiki, M., Sugano, 
N. and Inoue, Y. 2014. Treatment strategies for aor-
tic and peripheral prosthetic graft infection. Surg 
Today. 44(3):466-71.
7. Jones, K.G., Bell, R.E., Sabbarwal, T., Aukett, M., 
Reidy, J.T. and Tavlor, P.R. 2005. Treatment of 
mycotic aortic aneurysms with endoluminal grafts. 
Eur J Vasc Endovasc Surg 29:139-144.
8. Leobon, B., Roux, D., Mugniot, A., Rousseau, H., 
Cerene, A., Glock, Y., et al. 2002. Endovascular 
treatment of thoracic aortic fistulae. Ann Thorac 
Surg 74:247-249.
9. Laohapensang, K., Aworn, S., Orrapi, S. and 
Rutherford, R.B. 2012. Management of the infected 
aorto-iliac aneurysm. Ann Vasc Dis 5:334-341.
10. Patel, H.J., William, D.W., Upchurch, G.K., Dasika, 
N.I., Eliason, J.L. and Deeb, G.M. 2009. Late out-
come of endovascular repair for the infected thoracic 
aorta. Ann Thorac Surg 87:1366-1371.
11. Pirretti, S., Bozzani, A., Arici, V. and Odero, A. 
2002. Endovascular treatment of acute haemoptysis 
secondary to aorto-bronchial fistula. Eur J Vas En-
dovasc Surg 32:366-368.
12. Reisenmann, P.J., Books, J.D. and Farber, M.A. 
2009. Thoracic endovascular aottic repair of aorto-
